The U.S. FDA has approved a new indication for Ocular Therapeutix’s Dextenza® (dexamethasone ophthalmic insert) to treat ocular itching associated with allergic conjunctivitis.
- Dextenza is a small insert placed by a healthcare professional inside a natural opening in the lower eyelid through which tears drain. It contains a 30-day supply of dexamethasone (a corticosteroid and current standard of care) and releases 0.4mg of the drug per
- First FDA approved in 2018, Dextenza is also indicated to treat ocular inflammation and pain following ophthalmic surgery.
